Download PDF
Horm Metab Res 2005; 37(6): 375-379
DOI: 10.1055/s-2005-870152
Review
© Georg Thieme Verlag KG Stuttgart · New York

Menin and TGF-β Superfamily Member Signaling via the Smad Pathway in Pituitary, Parathyroid and Osteoblast

G.  N.  Hendy1 , H.  Kaji2 , H.  Sowa2 , J.-J.  Lebrun1 , L.  Canaff1
  • 1Departments of Medicine, Physiology and Human Genetics, McGill University, and Calcium Research Laboratory and Hormones and Cancer Research Unit, Royal Victoria Hospital, Montreal, Quebec, Canada
  • 2Division of Endocrinology/Metabolism, Neurology and Haematology/Oncology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Further Information

Publication History

Received 10 January 2005

Accepted after revision 25 March 2005

Publication Date:
07 July 2005 (online)

Also available at
    Permissions and Reprints

Abstract

Pituitary: Menin is a Smad3-interacting protein; inactivation of menin blocks transforming growth factor (TGF)-β and activin signaling, antagonizing their growth-inhibitory properties in anterior pituitary cells. Menin is also required for the activin-induced inhibition of prolactin expression mediated by the Smads and the transcription factor, Pit-1. The interaction between menin and Smad3 is direct. Parathyroid: In cultured parathyroid cells from uremic hemodialysis patients, in which the menin signaling pathways are probably still intact, menin inactivation achieved by menin antisense oligonucleotides leads to loss of TGF-β inhibition of parathyroid cell proliferation and parathyroid hormone (PTH) secretion. Moreover, TGF-β does not affect the proliferation and PTH production of parathyroid cells from multiple endocrine neoplasia type 1 (MEN1) patients. Osteoblast: Men1-null mouse fetuses that die at day 12 or earlier have cranial/facial hypoplasias implicating menin in bone development. Menin is required for the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. This is achieved by menin interacting physically and functionally with bone morphogenetic protein (BMP)-2 regulated Smads, such as Smad1 and Smad5, and the key osteoblast regulator, Runx2. These interactions are lost as the committed osteoblasts differentiate further at which time menin interacts with Smad3, mediating the negative regulation of Runx2 by TGF-β. Menin also suppresses osteoblast maturation, partly by inhibiting the differentiation actions of JunD.

Key words

Menin - Parathyroid - Anterior pituitary - Osteoblast

References

  • 1 Chandrasekharappa S C, Guru S C, Manickam P, Olufemi S E, Collins F S, Emmert-Buck M R, Debelenko L V, Zhuang Z, Lubensky I A, Liotta L A, Crabtree J S, Wang Y, Roe B A, Weisemann J, Boguski M S, Agarwal S K, Kester M B, Kim Y S, Heppner C, Dong Q, Spiegel A M, Burns A L, Marx S J. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science (Wash.  DC). 1997;  276 404-407
    CrossrefPubMedSearch in Google Scholar
  • 2 Guru S C, Goldsmith P K, Burns A L, Marx S J, Spiegel A M, Collins F S, Chandrasekharappa S C. Menin, the product of the MEN1 gene, is a nuclear protein.  Proc Natl Acad Sci USA. 1998;  95 1630-1634
    CrossrefPubMedSearch in Google Scholar
  • 3 Kaji H, Canaff L, Goltzman D, Hendy G N. Cell cycle regulation of menin expression.  Cancer Res. 1999;  59 5097-5101
    PubMedSearch in Google Scholar
  • 4 The European Consortium on MEN1 . Identification of the multiple endocrine neoplasia type 1 (MEN1) gene.  Hum Mol Genet. 1997;  6 1177-1183
    CrossrefPubMedSearch in Google Scholar
  • 5 Crabtree J S, Scachetti P C, Ward J M, Garrett-Beal L, Emmert-Buck M R, Edgemon K A, Lorang D, Libutti S K, Chandrasekharappa S C, Marx S J, Spiegel A M, Collins F S. A mouse model of multiple endocrine neoplasia type 1 develops multiple endocrine tumors.  Proc Natl Acad Sci USA. 2001;  98 1118-1123
    CrossrefPubMedSearch in Google Scholar
  • 6 Bertolino P, Tong W M, Galendo D, Wang Z Q, Zhang C X. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.  Mol Endocrinol. 2003;  17 1880-1892
    CrossrefPubMedSearch in Google Scholar
  • 7 Bertolino P, Radovanovic I, Casse H, Aguzzi A, Wang Z Q, Zhang C X. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs.  Mech Dev. 2003;  120 549-560
    CrossrefPubMedSearch in Google Scholar
  • 8 Hughes C M, Rozenblatt-Rosen O, Milne T A, Copeland T D, Levine S S, Lee J C, Hayes D N, Shanmugan K S, Bhattachariee A, Biondi C A, Kay G F, Hayward N K, Hess J L, Meyerson M. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.  Mol Cell. 2004;  13 587-597
    CrossrefPubMedSearch in Google Scholar
  • 9 Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero D J, Kitabayushi I, Herr W, Cleary M L. Leukemia proto-oncogene MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.  Mol Cell Biol. 2004;  24 5639-5649
    CrossrefPubMedSearch in Google Scholar
  • 10 Suphapeetiporn K, Greally J M, Walpita D, Ashley T, Bale A E. MEN1 tumor-suppressor protein localizes to telomeres during meiosis.  Gene Chromosome Cancer. 2002;  35 81-85
    PubMedSearch in Google Scholar
  • 11 Lin S Y, Elledge S J. Multiple tumor suppressor pathways negatively regulate telomerase.  Cell. 2003;  113 881-889
    CrossrefPubMedSearch in Google Scholar
  • 12 Sukhodolets K E, Hickman A B, Agarwal S K, Sukhodolets M V, Obungu V H, Novotny E A, Crabtree J S, Chandrasekharappa S C, Collins F S, Spiegel A M, Burns A L, Marx S J. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene.  Mol Cell Biol. 2003;  23 493-509
    CrossrefPubMedSearch in Google Scholar
  • 13 Jin S, Mao H, Schnepp R W, Sykes S M, Silva A C, D’Andrea A D, Hua X. Menin associates with FANCD2, a protein involved in repair of DNA damage.  Cancer Res. 2003;  63 4204-4210
    PubMedSearch in Google Scholar
  • 14 Poisson A, Zablewska B, Gaudray P. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1.  Cancer Lett. 2003;  189 1-10
    CrossrefPubMedSearch in Google Scholar
  • 15 Dockray G J. Keeping neuroendocrine cells in check: roles for TGFβ, Smads, and menin?.  Gut. 2003;  52 1237-1239
    CrossrefPubMedSearch in Google Scholar
  • 16 Shi Y, Massaque J. Mechanisms of TGF-β signaling from cell membrane to the nucleus.  Cell. 2003;  113 685-700
    CrossrefPubMedSearch in Google Scholar
  • 17 ten Dijke P, Miyazono K, Heldin C H. Signaling inputs converge on nuclear effectors in TGF-β signaling.  Trends biochem Sci. 2000;  25 64-70
    CrossrefPubMedSearch in Google Scholar
  • 18 Markowitz S, Wag J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R S, Zborowska E, Kinzler K W, Vogelstein B. et al . Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.  Science. 1995;  268 1336-1338
    PubMedSearch in Google Scholar
  • 19 Goggins M, Shekher M, Turnacioglu K, Yeo C J, Hruban R H, Kern S E. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.  Cancer Res. 1998;  58 5329-5332
    PubMedSearch in Google Scholar
  • 20 Chen T, de Vries E GE, Hollema H, Yegen H A, Vellucci V F, Strickler H D, Hildesheim A, Reiss M. Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma.  Int J Cancer. 1999;  82 43-51
    CrossrefPubMedSearch in Google Scholar
  • 21 Pasche B, Kolachana P, Nafa K, Satagopan J, Chen Y G, Lo R S, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massague J, Offit K. TbetaR-I(6A) is a candidate tumor susceptibility allele.  Cancer Res. 1999;  59 5678-5682
    PubMedSearch in Google Scholar
  • 22 Chen T, Carter D, Garrigue-Antar l, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.  Cancer Res. 1998;  58 4805-4810
    PubMedSearch in Google Scholar
  • 23 Hahn S A, Schutte M, Hoque A T, Moskaluk C a, da Costa L T, Rozenblum E, Weinstein C L, Fischer A, Yeo C J, Hruban R H, Kern S E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.  Science. 1996;  271 350-353
    CrossrefPubMedSearch in Google Scholar
  • 24 Barrett M T, Schutte M, Kern S E, Reid B J. Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma.  Cancer Res. 1996;  56 4351-4353
    PubMedSearch in Google Scholar
  • 25 Kim S K, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman W N, Hong W K, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma.  Cancer Res. 1996;  56 2519-2521
    PubMedSearch in Google Scholar
  • 26 Kawate S, Takenoshita S, Ohwada S, Mogi A, Fukusato T, Makita F, Kuwano H, Morishita Y. Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma.  Int J Oncol. 1999;  14 127-131
    PubMedSearch in Google Scholar
  • 27 Kong X T, Choi S H, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K, Hayashi Y. Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18 - 1 genes in neuroblastoma.  Cancer Res. 1997;  57 3772-3778
    PubMedSearch in Google Scholar
  • 28 Yokota T, Matsumoto S, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nakamura Y, Emi M. Mapping of a breast cancer tumor suppressor gene locus to a 4-cM interval on chromosome 18q21.  Jpn J Cancer Res. 1997;  88 959-964
    PubMedSearch in Google Scholar
  • 29 Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi T, Saji S, Shimokata K, Takahashi T, Takahashi T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers.  Cancer Res. 1996;  56 2718-2720
    PubMedSearch in Google Scholar
  • 30 Eppert K, Scherer S W, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui L C, Bapat B, Gallinger S, Andrulis I L, Thomsen G H, Wrana J L, Attisano L. MADR1 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.  Cell. 1996;  86 543-552
    CrossrefPubMedSearch in Google Scholar
  • 31 Takagi Y, Koumura H, Futamura M, Aoki S, Yamaguchi K, Kida H, Tanemura H, Shimokawa K, Saji S. Somatic alterations of the SMAD-2 gene in human colorectal cancers.  Br J Cancer. 1998;  78 1152-1155
    CrossrefPubMedSearch in Google Scholar
  • 32 Riggins G J, Thiagalingam S, Rozenblum E, Weinstein C L, Kern S E, Hamilton S R, Willson J K, Markowitz S D, Kinzler K W, Vogelstein B. Mad-related genes in the human.  Nat Genet. 1996;  13 347-349
    PubMedSearch in Google Scholar
  • 33 Kaji H, Canaff L, Lebrun J-J, Goltzman D, Hendy G N. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling.  Proc Natl Acad Sci USA. 2001;  98 3837-3842
    CrossrefPubMedSearch in Google Scholar
  • 34 Canaff L, Hendy G N. Menin interacts directly with the TGF-β signaling molecule Smad3 and MEN1 missense mutations within the interacting region have impaired TGF-β transcriptional activity.  J Int Med. 2004;  255 721-722, Abs 7004
    PubMedSearch in Google Scholar
  • 35 Stroschein S L, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein.  Science. 1999;  286 771-774
    CrossrefPubMedSearch in Google Scholar
  • 36 Luo K, Stroschein S L, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGF-β signaling.  Genes Dev. 1999;  13 2196-2206
    CrossrefPubMedSearch in Google Scholar
  • 37 Theodoropoulou M, Cavallari I, Barzon L, D’Agostino D M, Ferro T, Arzberger T, Grubler Y, Schaaf L, Losa M, Fallo F, Ciminale V, Stalla G K, Pagotto U. Differential expression of menin in sporadic pituitary adenomas.  Endocrine-Related Cancer. 2004;  11 333-344
    CrossrefPubMedSearch in Google Scholar
  • 38 Murata T, Ying S. Transforming growth factor-β and activin inhibit basal secretion of prolactin in a pituitary monolayer culture system.  Proc Soc Exp Biol Med. 1991;  198 599-605
    PubMedSearch in Google Scholar
  • 39 Lacerte A, Lee E-H, Reynaud R, Canaff L, De Guise C, Devost D, Ali S, Hendy G N, Lebrun J-J. Activin inhibits prolactin expression and cell growth through Smads, Pit-1 and Menin.  Molec Endocrinol. 2004;  18 1558-1569
    CrossrefPubMedSearch in Google Scholar
  • 40 Sowa H, Kaji H, Kitazawa R, Kitazawa S, Tsukamoto T, Yano S, Tsukada T, Canaff L, Hendy G N, Sugimoto T, Chihara K. Menin inactivation leads to loss to transforming growth factor β inhibition of parathyroid cell proliferation and parathyroid hormone secretion.  Cancer Res. 2004;  64 2223-2228
    PubMedSearch in Google Scholar
  • 41 Shattuck T M, Costa J, Bernstein M, Jensen R T, Chung D C, Arnold A. Mutational analysis of Smad3, a candidate tumor suppressor implicated in TGF-β and menin pathways, in parathyroid adenomas and enteropancreatic endocrine tumors.  J Clin Endocrineol Metab. 2002;  87 3911-3914
    PubMedSearch in Google Scholar
  • 42 Yanagisawa , J , Yanagi Y, Masuhiro Y, Suzawa M, Wantanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazone K, Kato S. Convergence of transforming growth factor β and vitamin D signaling pathways on Smad transcriptional coactivators.  Science. 1999;  283 1317-1321
    CrossrefPubMedSearch in Google Scholar
  • 43 Subramaniam N, Leong G M, Cock T A, Flanagan J L, Fong C, Eisman J A, Kouzmenko A P. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-β signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements.  J Biol Chem. 2001;  276 15 741-15 746
    PubMedSearch in Google Scholar
  • 44 Kremer R, Bolivar I, Goltzman D, Hendy G N. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells.  Endocrinology. 1989;  125 935-941
    PubMedSearch in Google Scholar
  • 45 Otto W R, Rao J. Tomorrow’s skeleton staff: mesenchymal stem cells and the repair of bone and cartilage.  Cell Prolif. 2004;  37 97-110
    CrossrefPubMedSearch in Google Scholar
  • 46 Sowa H, Kaji H, Canaff L, Hendy G N, Tsukamoto T, Yamaguchi T, Miyazono K, Sugimoto T, Chihara K. Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage.  J Biol Chem. 2003;  278 21 058-21 069
    PubMedSearch in Google Scholar
  • 47 Sowa H, Kaji H, Hendy G N, Canaff L, Komori T, Sugimoto T, Chihara K. Menin is required for bone morphogenetic protein 2- and transforming growth factor β-regulated osteoblastic differentiation through interaction with Smads and Runx2.  J Biol Chem. 2004;  279 40 267-40 275
    PubMedSearch in Google Scholar
  • 48 Naito J, Kaji H, Sowa H, Hendy G N, Sugimoto T, Chihara K. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD.  J Biol Chem. 2005;  280 4785-4791
    CrossrefPubMedSearch in Google Scholar
  • 49 Novotny E A, Prasad N, Crabtree J, Ji Y-M, Elkahloun A, Agarwal S, Lumelsky N, Marx S, Spiegel A, Collins F, Chandrasekharappa S. Characterization of murine Men1-/- cell lines established to study the function of menin. Eighth International Workshop on Multiple Endocrine Neoplasia. Van Andel Institute Grand Rapids, Michigan, USA; June 15 - 18, 2002: Abs. 24
    Search in Google Scholar

G. N. Hendy, Ph. D.

Calcium Research Laboratory, Royal Victoria Hospital

Rm. H4.67 · 687 Pine Avenue West · Montreal · QC H3A 1A1 · Canada

Phone: +1 (514) 843-1632

Fax: +1 (514) 843-1712

Email: geoffrey.hendy@mcgill.ca